Video

Dr. Gandara on Patient Selection for Molecular Testing

Dr. David Gandara from the UC Davis Comprehensive Cancer Center on Patient Selection for Molecular Testing in Lung Cancer

David R. Gandara, MD, Director, Thoracic Oncology Program, University of California, Davis Comprehensive Cancer Center, discusses factors that help determine which patients with lung cancer should be tested for molecular aberrations.

Gandara believes that the best approach for determining whom to test is still debatable. However, new guidelines from IASLC and CAP recommend that all patients with adenocarcinoma should be tested for molecular abnormalities.

For EGFR and ALK aberrations, it has been suggested that the most cost-effective approach involves testing only never-smokers who have adenocarcinomas. However, Gandara explains that many former or light smokers are testing positive. The increasing frequency of these reports confirms the recommendations within the guidelines to test all patients with adenocarcinoma.

Moreover, Gandara notes that some patients with squamous cell carcinoma are also exhibiting ample actionable abnormalities that warrant molecular testing.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity